Conference Coverage

VIDEO: Adding methotrexate to a biologic may help achieve treatment goal


 

AT SDEF HAWAII DERMATOLOGY SEMINAR

– Combining methotrexate with a biologic is an off-label use for psoriasis patients but is supported by information from the psoriatic arthritis literature, said J. Mark Jackson, MD, of the University of Louisville (Ky.).

As for dosage, “I do think we can use less methotrexate in combination” with a biologic for psoriasis when using methotrexate alone, he noted. “It’s like the addition of a spice to the right dish,” he added. Patients may need “just a little bit to get them over the edge and really get them to that efficacy point that creates the success that you need.”

Dr. Jackson disclosed financial relationships with companies including AbbVie, Amgen, Celgene, Dermira, Galderma, Genentech, Janssen, Lilly, Medimetriks, Merck, Novartis, Pfizer, Promius, and Top MD.

SDEF and this news organization are owned by the same parent organization.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Initial suboptimal responders to secukinumab usually bloom later
MDedge Dermatology
Medicare payments set for infliximab biosimilar Inflectra
MDedge Dermatology
Debunking Psoriasis Myths: Do Systemic Steroids Used in Psoriasis Patients Cause Pustular Psoriasis?
MDedge Dermatology
Childhood psoriasis negatively impacts parental QOL
MDedge Dermatology
Fixed combination topical shows promise for psoriasis
MDedge Dermatology
Bone fractures more likely to occur in psoriasis, PsA patients
MDedge Dermatology
Severe Henoch-Schönlein Purpura Complicating Infliximab Therapy for Ulcerative Colitis
MDedge Dermatology
FDA opens abbreviated approval pathway for interchangeable biosimilars
MDedge Dermatology
MTX side effects limit patient use
MDedge Dermatology
VIDEO: Interchangeability of biosimilars and parent compounds raise potential efficacy issues
MDedge Dermatology